Upstate Active Clinical Trials
Study Title:
A Randomized, Double Blind, Placebo controlled, dose assessment phase II study toevaluate the safety and efficacy of CCX168 in subjects with anti-neutrophil cytoplasmic antibody (ANCAAssociated
Vasculitis)
What is the purpose of the study? (in Layman's terms, please describe the study)
The main safety objective of this study is to evaluate the safety and tolerability of CCX168 when it is given to patients who are receiving the standard therapy for AAV.This study will also assess the efficacy of the treatment with CCX168 in combination with the standard therapy in the treatment of AAV.
This study will also evaluate if CCX168 improves your symptoms, your kidney function (if you have kidney disease involvement) and your overall disease activity when compared to the treatment with placebo (“sugar pills”)
Upstate Institutional Review Board (IRB) Number:
732499Study/Protocol ID:
Protocol CL003_168Study Phase:
Phase IIPatient Age Group:
AdultsPrincipal Investigator:
Sriram S NarsipurWho can I contact for more information?
Name: Linda L Spillett, CCRP
Phone: 315-464-9017
Email: spilletl@upstate.edu